vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Freshworks Inc. (FRSH). Click either name above to swap in a different company.
Freshworks Inc. is the larger business by last-quarter revenue ($222.7M vs $168.4M, roughly 1.3× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 14.5%). Over the past eight quarters, Freshworks Inc.'s revenue compounded faster (16.1% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Freshworks Inc. is a cloud-based software-as-a-service company, founded in 2010 in Chennai, India. The company provides cloud-based tools for customer relationship management (CRM), IT service management (ITSM), and e-commerce marketing.
ESPR vs FRSH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $222.7M |
| Net Profit | — | $191.4M |
| Gross Margin | — | 85.6% |
| Operating Margin | 50.6% | 17.8% |
| Net Margin | — | 86.0% |
| Revenue YoY | 143.7% | 14.5% |
| Net Profit YoY | — | 974.2% |
| EPS (diluted) | $0.32 | $0.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $222.7M | ||
| Q3 25 | $87.3M | $215.1M | ||
| Q2 25 | $82.4M | $204.7M | ||
| Q1 25 | $65.0M | $196.3M | ||
| Q4 24 | $69.1M | $194.6M | ||
| Q3 24 | $51.6M | $186.6M | ||
| Q2 24 | $73.8M | $174.1M | ||
| Q1 24 | $137.7M | $165.1M |
| Q4 25 | — | $191.4M | ||
| Q3 25 | $-31.3M | $-4.7M | ||
| Q2 25 | $-12.7M | $-1.7M | ||
| Q1 25 | $-40.5M | $-1.3M | ||
| Q4 24 | — | $-21.9M | ||
| Q3 24 | $-29.5M | $-30.0M | ||
| Q2 24 | $-61.9M | $-20.2M | ||
| Q1 24 | $61.0M | $-23.3M |
| Q4 25 | — | 85.6% | ||
| Q3 25 | — | 84.7% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 84.8% | ||
| Q4 24 | — | 84.9% | ||
| Q3 24 | — | 84.0% | ||
| Q2 24 | — | 83.8% | ||
| Q1 24 | — | 84.3% |
| Q4 25 | 50.6% | 17.8% | ||
| Q3 25 | -11.4% | -3.5% | ||
| Q2 25 | 8.6% | -4.2% | ||
| Q1 25 | -34.0% | -5.3% | ||
| Q4 24 | -6.4% | -12.2% | ||
| Q3 24 | -31.0% | -20.8% | ||
| Q2 24 | 3.5% | -25.1% | ||
| Q1 24 | 52.5% | -19.5% |
| Q4 25 | — | 86.0% | ||
| Q3 25 | -35.9% | -2.2% | ||
| Q2 25 | -15.4% | -0.8% | ||
| Q1 25 | -62.2% | -0.7% | ||
| Q4 24 | — | -11.3% | ||
| Q3 24 | -57.2% | -16.1% | ||
| Q2 24 | -83.9% | -11.6% | ||
| Q1 24 | 44.3% | -14.1% |
| Q4 25 | $0.32 | $0.66 | ||
| Q3 25 | $-0.16 | $-0.02 | ||
| Q2 25 | $-0.06 | $-0.01 | ||
| Q1 25 | $-0.21 | $0.00 | ||
| Q4 24 | $-0.14 | $-0.07 | ||
| Q3 24 | $-0.15 | $-0.10 | ||
| Q2 24 | $-0.33 | $-0.07 | ||
| Q1 24 | $0.34 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $781.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.0B |
| Total Assets | $465.9M | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $781.4M | ||
| Q3 25 | $92.4M | $813.2M | ||
| Q2 25 | $86.1M | $926.2M | ||
| Q1 25 | $114.6M | $995.3M | ||
| Q4 24 | $144.8M | $1.1B | ||
| Q3 24 | $144.7M | $1.1B | ||
| Q2 24 | $189.3M | $1.0B | ||
| Q1 24 | $226.6M | $1.2B |
| Q4 25 | $-302.0M | $1.0B | ||
| Q3 25 | $-451.4M | $851.5M | ||
| Q2 25 | $-433.5M | $984.6M | ||
| Q1 25 | $-426.2M | $1.1B | ||
| Q4 24 | $-388.7M | $1.1B | ||
| Q3 24 | $-370.2M | $1.1B | ||
| Q2 24 | $-344.2M | $1.1B | ||
| Q1 24 | $-294.3M | $1.1B |
| Q4 25 | $465.9M | $1.6B | ||
| Q3 25 | $364.0M | $1.4B | ||
| Q2 25 | $347.1M | $1.5B | ||
| Q1 25 | $324.0M | $1.5B | ||
| Q4 24 | $343.8M | $1.6B | ||
| Q3 24 | $314.1M | $1.6B | ||
| Q2 24 | $352.3M | $1.5B | ||
| Q1 24 | $373.1M | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $62.3M |
| Free Cash FlowOCF − Capex | — | $60.1M |
| FCF MarginFCF / Revenue | — | 27.0% |
| Capex IntensityCapex / Revenue | 0.0% | 1.0% |
| Cash ConversionOCF / Net Profit | — | 0.33× |
| TTM Free Cash FlowTrailing 4 quarters | — | $236.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $62.3M | ||
| Q3 25 | $-4.3M | $63.5M | ||
| Q2 25 | $-31.4M | $58.6M | ||
| Q1 25 | $-22.6M | $58.0M | ||
| Q4 24 | $-35.0M | $41.4M | ||
| Q3 24 | $-35.3M | $42.3M | ||
| Q2 24 | $-7.2M | $36.3M | ||
| Q1 24 | $53.8M | $40.6M |
| Q4 25 | — | $60.1M | ||
| Q3 25 | — | $61.7M | ||
| Q2 25 | — | $58.2M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | — | $36.3M | ||
| Q3 24 | $-35.5M | $41.3M | ||
| Q2 24 | $-7.3M | $34.0M | ||
| Q1 24 | $53.8M | $39.9M |
| Q4 25 | — | 27.0% | ||
| Q3 25 | — | 28.7% | ||
| Q2 25 | — | 28.4% | ||
| Q1 25 | — | 28.9% | ||
| Q4 24 | — | 18.7% | ||
| Q3 24 | -68.7% | 22.1% | ||
| Q2 24 | -9.9% | 19.5% | ||
| Q1 24 | 39.0% | 24.1% |
| Q4 25 | 0.0% | 1.0% | ||
| Q3 25 | 0.0% | 0.8% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 0.7% | ||
| Q4 24 | 0.0% | 2.6% | ||
| Q3 24 | 0.3% | 0.6% | ||
| Q2 24 | 0.1% | 1.3% | ||
| Q1 24 | 0.1% | 0.4% |
| Q4 25 | — | 0.33× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FRSH
| Subscription Services Software Licenses And Maintenance | $220.2M | 99% |
| Professional Services | $2.5M | 1% |
